Theravance Biopharma Inc (NASDAQ:TBPH) – Research analysts at Leerink Swann lowered their FY2017 earnings per share (EPS) estimates for Theravance Biopharma in a research note issued to investors on Thursday. Leerink Swann analyst G. Porges now expects that the biopharmaceutical company will earn ($4.96) per share for the year, down from their prior forecast of ($4.95). Leerink Swann currently has a “Outperform” rating and a $48.00 target price on the stock. Leerink Swann also issued estimates for Theravance Biopharma’s Q1 2018 earnings at $0.71 EPS, Q2 2018 earnings at ($1.24) EPS, Q3 2018 earnings at ($1.39) EPS, Q4 2018 earnings at ($1.15) EPS, FY2018 earnings at ($3.08) EPS, FY2019 earnings at ($4.44) EPS, FY2020 earnings at ($0.58) EPS and FY2021 earnings at ($1.28) EPS.
Other equities research analysts have also issued reports about the company. BidaskClub raised Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Friday. ValuEngine lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald reissued a “buy” rating and issued a $55.00 price target on shares of Theravance Biopharma in a research report on Tuesday, November 7th. Robert W. Baird reissued a “sell” rating and issued a $22.00 price target on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Finally, Needham & Company LLC restated a “buy” rating on shares of Theravance Biopharma in a research note on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Theravance Biopharma currently has an average rating of “Hold” and an average target price of $42.00.
A number of large investors have recently made changes to their positions in TBPH. Wells Fargo & Company MN grew its stake in Theravance Biopharma by 174.8% in the 2nd quarter. Wells Fargo & Company MN now owns 88,688 shares of the biopharmaceutical company’s stock valued at $3,533,000 after purchasing an additional 56,418 shares during the period. TIAA CREF Investment Management LLC grew its stake in Theravance Biopharma by 21.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 154,158 shares of the biopharmaceutical company’s stock valued at $6,142,000 after purchasing an additional 27,472 shares during the period. BlackRock Inc. grew its stake in Theravance Biopharma by 3.6% in the 2nd quarter. BlackRock Inc. now owns 3,638,838 shares of the biopharmaceutical company’s stock valued at $144,972,000 after purchasing an additional 126,393 shares during the period. Amalgamated Bank bought a new position in Theravance Biopharma in the 2nd quarter valued at $214,000. Finally, New York State Common Retirement Fund grew its stake in Theravance Biopharma by 9.2% in the 2nd quarter. New York State Common Retirement Fund now owns 46,300 shares of the biopharmaceutical company’s stock valued at $1,845,000 after purchasing an additional 3,899 shares during the period. Hedge funds and other institutional investors own 86.04% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/theravance-biopharma-inc-to-post-fy2017-earnings-of-4-96-per-share-leerink-swann-forecasts-tbph.html.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.